GenMark Diagnostics

GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions. The company develops and commercializes instruments and multiplex molecular panels based on its proprietary eSensor electrochemical detection technology. The company's technologies include: eSensor technology, which is based on the principles of deoxyribonucleic acid, hybridization and electrochemical detection; and digital microfluidics, which is a technique for moving small droplets of liquid using electrowetting, a process for making a surface hydrophobic or hydrophilic based on the application of a voltage to a surface.
  • TickerGNMK
  • ISINUS3723091043
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year 2020 Financial Highlights Total revenue of $171.6 million, an increase of 95% over 2019 ePlex® revenue of $152.6 million, an increase of 155% over 2019 Gross margin of 40%, co...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Car...

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference. GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com ...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

L'étude souligne la valeur clinique potentielle des panels pour l'iden...

L'étude souligne la valeur clinique potentielle des panels pour l'identification d'hémocultures ePlex® Le grand centre hospitalier universitaire de Grenoble, en France, démontre que les résultats des panels pour l'identification d'hémocultures ePlex auraient permis de modifier le traitement antimicrobien chez 45 % des patients CARLSBAD, Calif., 16 févr. 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ : GNMK), fournisseur de premier plan en matière de systèmes de tests de diagnostic moléculaire multiplex automatisés, a annoncé aujourd'hui la publication d'un manuscrit dans Fro...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID P...

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Ide...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financ...

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. webs...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year 2020 Financial Highlights Total revenue of $171.6 million, an increase of 95% over 2019 ePlex® revenue of $152.6 million, an increase of 155% over 2019 Gross margin of 40%, co...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Car...

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference. GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com ...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

L'étude souligne la valeur clinique potentielle des panels pour l'iden...

L'étude souligne la valeur clinique potentielle des panels pour l'identification d'hémocultures ePlex® Le grand centre hospitalier universitaire de Grenoble, en France, démontre que les résultats des panels pour l'identification d'hémocultures ePlex auraient permis de modifier le traitement antimicrobien chez 45 % des patients CARLSBAD, Calif., 16 févr. 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ : GNMK), fournisseur de premier plan en matière de systèmes de tests de diagnostic moléculaire multiplex automatisés, a annoncé aujourd'hui la publication d'un manuscrit dans Fro...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID P...

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Ide...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financ...

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. webs...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year 2020 Financial Highlights Total revenue of $171.6 million, an increase of 95% over 2019 ePlex® revenue of $152.6 million, an increase of 155% over 2019 Gross margin of 40%, co...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Car...

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference. GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com ...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

L'étude souligne la valeur clinique potentielle des panels pour l'iden...

L'étude souligne la valeur clinique potentielle des panels pour l'identification d'hémocultures ePlex® Le grand centre hospitalier universitaire de Grenoble, en France, démontre que les résultats des panels pour l'identification d'hémocultures ePlex auraient permis de modifier le traitement antimicrobien chez 45 % des patients CARLSBAD, Calif., 16 févr. 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ : GNMK), fournisseur de premier plan en matière de systèmes de tests de diagnostic moléculaire multiplex automatisés, a annoncé aujourd'hui la publication d'un manuscrit dans Fro...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID P...

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Ide...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financ...

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. webs...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year 2020 Financial Highlights Total revenue of $171.6 million, an increase of 95% over 2019 ePlex® revenue of $152.6 million, an increase of 155% over 2019 Gross margin of 40%, co...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Car...

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference. GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com ...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

L'étude souligne la valeur clinique potentielle des panels pour l'iden...

L'étude souligne la valeur clinique potentielle des panels pour l'identification d'hémocultures ePlex® Le grand centre hospitalier universitaire de Grenoble, en France, démontre que les résultats des panels pour l'identification d'hémocultures ePlex auraient permis de modifier le traitement antimicrobien chez 45 % des patients CARLSBAD, Calif., 16 févr. 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ : GNMK), fournisseur de premier plan en matière de systèmes de tests de diagnostic moléculaire multiplex automatisés, a annoncé aujourd'hui la publication d'un manuscrit dans Fro...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID P...

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Ide...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financ...

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. webs...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results

GenMark Diagnostics Reports Fourth Quarter and Full Year 2020 Results CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year 2020 Financial Highlights Total revenue of $171.6 million, an increase of 95% over 2019 ePlex® revenue of $152.6 million, an increase of 155% over 2019 Gross margin of 40%, co...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Car...

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference. GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com ...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

L'étude souligne la valeur clinique potentielle des panels pour l'iden...

L'étude souligne la valeur clinique potentielle des panels pour l'identification d'hémocultures ePlex® Le grand centre hospitalier universitaire de Grenoble, en France, démontre que les résultats des panels pour l'identification d'hémocultures ePlex auraient permis de modifier le traitement antimicrobien chez 45 % des patients CARLSBAD, Calif., 16 févr. 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ : GNMK), fournisseur de premier plan en matière de systèmes de tests de diagnostic moléculaire multiplex automatisés, a annoncé aujourd'hui la publication d'un manuscrit dans Fro...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID P...

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Ide...

 PRESS RELEASE
GNMK GenMark Diagnos... (Health Care)

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financ...

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. webs...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch